MedTrace Logo

A Study Using 18F-FAZA and PET Scans to Study Hypoxia in Pancreatic Cancer

NCT01542177 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 30

Last updated 2022-05-05

No results posted yet for this study

Summary

This is a diagnostic study to look for low levels of oxygen (hypoxia) in pancreatic cancer using an imaging test called positron emission tomography (PET). Hypoxia can influence how pancreatic cancer grows and responds to treatments such as chemotherapy and radiotherapy. The use of PET scans to measure hypoxia may be better and simpler than the approaches used previously. This study will assess whether or not PET scans using a tracer called 18F-FAZA (18F-Fluoroazomycin Arabinoside) can provide useful information about hypoxia in pancreatic cancer. Also as part of the study, a blood sample will be taken to study biomarkers (substances in the body that may be important indicators of hypoxia and/or pancreatic cancer) that may be useful in studying pancreatic cancer and hypoxia.

Conditions

Sponsors & Collaborators

  • Canadian Cancer Society (CCS)

    collaborator OTHER

  • University Health Network, Toronto

    lead OTHER

Principal Investigators

  • David Hedley, MD · Princess Margaret Hospital, Canada

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-02-29
Primary Completion
2019-09-30
Completion
2019-09-30

Countries

  • Canada

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01542177 on ClinicalTrials.gov